个人中心 - 老虎社区

Rosechin

IP属地：未知

帖子 · 6帖子 · 6
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- RosechinRosechin
  ·2021-11-26
  Potential growth next year. I invest u
  非常抱歉，此主贴已删除
  2,818 1
  10
  分享
  举报
- RosechinRosechin
  ·2021-11-23
  thanks you for your sharing
  @我的投资笔记：
  分歧再现：一场人类的内卷，元宇宙可能毁灭我们，风险【第三期 Clip 3/5】
  分歧再现：一场人类的内卷，元宇宙可能毁灭我们，风险【第三期 Clip 3/5】
  2,949 评论
  点赞
  分享
  举报
- RosechinRosechin
  ·2021-11-20
  Potential growth in us and China market
  非常抱歉，此主贴已删除
  2,901 评论
  点赞
  分享
  举报
- RosechinRosechin
  ·2021-11-19
  Price is attractive now, time to invest for long term growth profits
  非常抱歉，此主贴已删除
  4,072 1
  4
  分享
  举报
- RosechinRosechin
  ·2021-11-19
  Potential
  Pfizer and BioNTech SE stocks climbed about 2% in premarket trading<blockquote>辉瑞和BioNTech SE股价在盘前交易中上涨约2%</blockquote>
  Pfizer and BioNTech SE stocks climbed about 2% in premarket trading after they received expanded U.S
  Pfizer and BioNTech SE stocks climbed about 2% in premarket trading<blockquote>辉瑞和BioNTech SE股价在盘前交易中上涨约2%</blockquote>
  2,023 3
  8
  分享
  举报
- RosechinRosechin
  ·2021-11-17
  Good to invest this sharr
  Online Gaming Business Drives Sohu's 37% Revenue Growth In Q3<blockquote>网络游戏业务推动搜狐第三季度营收增长37%</blockquote>
  
  Online Gaming Business Drives Sohu's 37% Revenue Growth In Q3<blockquote>网络游戏业务推动搜狐第三季度营收增长37%</blockquote>
  3,058 评论
  点赞
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4097912578278380","uuid":"4097912578278380","gmtCreate":1635413468377,"gmtModify":1636755272247,"name":"Rosechin","pinyin":"rosechin","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/b609bc0ae15909da0a6fbf0d048f7ebd","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":44,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.01.17","exceedPercentage":"93.24%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.44%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.03.14","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":877964719,"gmtCreate":1637879698497,"gmtModify":1637879698497,"author":{"id":"4097912578278380","authorId":"4097912578278380","name":"Rosechin","avatar":"https://static.tigerbbs.com/b609bc0ae15909da0a6fbf0d048f7ebd","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097912578278380","authorIdStr":"4097912578278380"},"themes":[],"htmlText":"Potential growth next year. I invest u","listText":"Potential growth next year. I invest u","text":"Potential growth next year. I invest u","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877964719","repostId":"2186916023","repostType":4,"isVote":1,"tweetType":1,"viewCount":2818,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875151836,"gmtCreate":1637627204225,"gmtModify":1637627204225,"author":{"id":"4097912578278380","authorId":"4097912578278380","name":"Rosechin","avatar":"https://static.tigerbbs.com/b609bc0ae15909da0a6fbf0d048f7ebd","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097912578278380","authorIdStr":"4097912578278380"},"themes":[],"htmlText":"thanks you for your sharing","listText":"thanks you for your sharing","text":"thanks you for your sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875151836","repostId":"842221902","repostType":1,"repost":{"id":842221902,"gmtCreate":1636184623202,"gmtModify":1636185728893,"author":{"id":"9000000000000115","authorId":"9000000000000115","name":"我的投资笔记","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"9000000000000115","authorIdStr":"9000000000000115"},"themes":[],"title":"","htmlText":"\n \n \n  分歧再现：一场人类的内卷，元宇宙可能毁灭我们，风险【第三期 Clip 3/5】\n \n","listText":"分歧再现：一场人类的内卷，元宇宙可能毁灭我们，风险【第三期 Clip 3/5】","text":"分歧再现：一场人类的内卷，元宇宙可能毁灭我们，风险【第三期 Clip 3/5】","images":[{"img":"https://static.tigerbbs.com/729c5b00e67961d971189bb5e6e4223d","width":"0","height":"0"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842221902","isVote":1,"tweetType":2,"object":{"id":"1dce0c352b1b44c38cee1a5665970d8e","tweetId":"842221902","title":"🟩【200万股票实盘】CRSR要开始上涨","videoUrl":"http://v.tigerbbs.com/1636184620301ede623db534dbf9ee783e2a02a5520a8.mp4","poster":"https://static.tigerbbs.com/729c5b00e67961d971189bb5e6e4223d","shareLink":"http://v.tigerbbs.com/1636184620301ede623db534dbf9ee783e2a02a5520a8.mp4"},"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2949,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876790918,"gmtCreate":1637360074724,"gmtModify":1637360074807,"author":{"id":"4097912578278380","authorId":"4097912578278380","name":"Rosechin","avatar":"https://static.tigerbbs.com/b609bc0ae15909da0a6fbf0d048f7ebd","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097912578278380","authorIdStr":"4097912578278380"},"themes":[],"htmlText":"Potential growth in us and China market","listText":"Potential growth in us and China market","text":"Potential growth in us and China market","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876790918","repostId":"2170614570","repostType":2,"isVote":1,"tweetType":1,"viewCount":2901,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876597757,"gmtCreate":1637329796423,"gmtModify":1637329804761,"author":{"id":"4097912578278380","authorId":"4097912578278380","name":"Rosechin","avatar":"https://static.tigerbbs.com/b609bc0ae15909da0a6fbf0d048f7ebd","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097912578278380","authorIdStr":"4097912578278380"},"themes":[],"htmlText":"Price is attractive now, time to invest for long term growth profits&nbsp;","listText":"Price is attractive now, time to invest for long term growth profits&nbsp;","text":"Price is attractive now, time to invest for long term growth profits","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/876597757","repostId":"2184899191","repostType":2,"isVote":1,"tweetType":1,"viewCount":4072,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876592132,"gmtCreate":1637329442489,"gmtModify":1637329442628,"author":{"id":"4097912578278380","authorId":"4097912578278380","name":"Rosechin","avatar":"https://static.tigerbbs.com/b609bc0ae15909da0a6fbf0d048f7ebd","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097912578278380","authorIdStr":"4097912578278380"},"themes":[],"htmlText":"Potential&nbsp;","listText":"Potential&nbsp;","text":"Potential","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/876592132","repostId":"1144455380","repostType":4,"repost":{"id":"1144455380","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637328728,"share":"https://www.laohu8.com/m/news/1144455380?lang=zh_CN&edition=full","pubTime":"2021-11-19 21:32","market":"us","language":"en","title":"Pfizer and BioNTech SE stocks climbed about 2% in premarket trading<blockquote>辉瑞和BioNTech SE股价在盘前交易中上涨约2%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1144455380","media":"Tiger Newspress","summary":"Pfizer and BioNTech SE stocks climbed about 2% in premarket trading after they received expanded U.S","content":"<p>Pfizer and BioNTech SE stocks climbed about 2%&nbsp;in premarket trading&nbsp;after&nbsp;they received expanded U.S. FDA emergency use authorization of booster to include individuals 18 and older.</p><p><blockquote>辉瑞和BioNTech SE的股价在盘前交易中上涨约2%，此前它们获得了美国FDA扩大的加强剂紧急使用授权，将18岁及以上的个人纳入其中。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/a0ee0544027cc35ceeb2a44c7caf0848\" tg-width=\"850\" tg-height=\"619\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/026143e67c4e4f63fadd07b9b23e1301\" tg-width=\"850\" tg-height=\"617\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Pfizer Inc.&nbsp;and BioNTech SE&nbsp;today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 18 years of age and older. The booster dose is to be administered at least six months after completion of the primary series, and is the same dosage strength as the doses in the primary series.</p><p><blockquote>辉瑞公司和BioNTech SE今天宣布，美国。美国食品药品监督管理局（FDA）已经扩大了辉瑞-BioNTech新冠肺炎疫苗加强剂量的紧急使用授权（EUA），以包括18岁及以上的个人。加强剂量将在主要系列完成后至少六个月施用，并且剂量强度与主要系列中的剂量相同。</blockquote></p><p> “As we near the two-year mark in our fight against COVID-19, we have reached another critical milestone with the expanded authorization of a booster dose of our COVID-19 vaccine in individuals 18 years and older,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “With boosters, more adults will now have the opportunity to help preserve a high-level of protection against this disease. We are grateful to the FDA for their rigorous review, and the action taken today that we hope will help accelerate our path out of this pandemic.”</p><p><blockquote>董事长Albert Bourla表示：“随着我们抗击COVID-19的斗争接近两年，我们达到了另一个重要里程碑，扩大了对18岁及以上人群的COVID-19疫苗加强剂量的授权。”辉瑞公司主席兼首席执行官。“有了加强剂，更多的成年人现在将有机会帮助保持针对这种疾病的高水平保护。我们感谢FDA的严格审查，以及今天采取的行动，我们希望这将有助于加速我们走出这场大流行。”</blockquote></p><p> “Today’s FDA decision is supported by clinical data showing robust immune responses following a booster dose of our vaccine, exceeding what has been seen even after the completion of the highly-effective two-dose primary schedule,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “These data suggest a booster dose of our vaccine has the potential to maintain a high-level of protection against tested variants, including Delta.”</p><p><blockquote>BioNTech首席执行官兼联合创始人Ugur Sahin医学博士表示：“今天FDA的决定得到了临床数据的支持，这些数据显示，我们的疫苗加强剂量后产生了强大的免疫反应，甚至超过了高效的两剂主要计划完成后的免疫反应。”“这些数据表明，我们疫苗的加强剂量有可能对包括Delta在内的经过测试的变种保持高水平的保护。”</blockquote></p><p> In October, the companies announced positive topline results from the trial showing that a booster dose administered to individuals who previously received the Pfizer-BioNTech primary two-dose series demonstrated a relative vaccine efficacy of 95% when compared to those who did not receive a booster. Thus far, these are the first and only efficacy data disclosed from any randomized, controlled COVID-19 vaccine booster trial. The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no new safety concerns identified.</p><p><blockquote>10月，两家公司宣布了该试验的积极顶线结果，显示与未接受过辉瑞-BioNTech初级两剂系列的个人相比，对之前接受过辉瑞-BioNTech初级两剂系列的个人进行的加强剂量显示出95%的相对疫苗功效。到目前为止，这是第一个也是唯一一个从任何随机、对照的新冠肺炎疫苗加强试验中披露的疗效数据。不良事件概况与疫苗的其他临床安全性数据基本一致，未发现新的安全性问题。</blockquote></p><p> A booster dose of the Pfizer-BioNTech COVID-19 Vaccine was previously authorized by the FDA for emergency use after completion of a primary series in individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2, as well as eligible individuals who have completed primary vaccination with a different authorized COVID-19 vaccine.</p><p><blockquote>辉瑞-BioNTech新冠肺炎疫苗的加强剂量此前已被FDA授权在完成初级系列后紧急使用，用于65岁及以上的个人、18至64岁的严重新冠肺炎高风险个人、18至64岁经常在机构或职业中暴露于新型冠状病毒的个人，以及已完成不同授权新冠肺炎疫苗初级疫苗接种的合格个人。</blockquote></p><p> Pfizer and BioNTech continue to supply the vaccine, including sufficient volume for boosters, under their existing supply agreement with the U.S. government, which continues through April 2022. The companies do not expect that today’s news will impact the existing supply agreements in place with governments and international health organizations around the world.</p><p><blockquote>辉瑞和BioNTech根据与美国政府现有的供应协议继续供应疫苗，包括足够的疫苗剂量，该协议将持续至2022年4月。这些公司预计今天的消息不会影响与世界各地政府和国际卫生组织的现有供应协议。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech SE stocks climbed about 2% in premarket trading<blockquote>辉瑞和BioNTech SE股价在盘前交易中上涨约2%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech SE stocks climbed about 2% in premarket trading<blockquote>辉瑞和BioNTech SE股价在盘前交易中上涨约2%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-19 21:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Pfizer and BioNTech SE stocks climbed about 2%&nbsp;in premarket trading&nbsp;after&nbsp;they received expanded U.S. FDA emergency use authorization of booster to include individuals 18 and older.</p><p><blockquote>辉瑞和BioNTech SE的股价在盘前交易中上涨约2%，此前它们获得了美国FDA扩大的加强剂紧急使用授权，将18岁及以上的个人纳入其中。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/a0ee0544027cc35ceeb2a44c7caf0848\" tg-width=\"850\" tg-height=\"619\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/026143e67c4e4f63fadd07b9b23e1301\" tg-width=\"850\" tg-height=\"617\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Pfizer Inc.&nbsp;and BioNTech SE&nbsp;today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 18 years of age and older. The booster dose is to be administered at least six months after completion of the primary series, and is the same dosage strength as the doses in the primary series.</p><p><blockquote>辉瑞公司和BioNTech SE今天宣布，美国。美国食品药品监督管理局（FDA）已经扩大了辉瑞-BioNTech新冠肺炎疫苗加强剂量的紧急使用授权（EUA），以包括18岁及以上的个人。加强剂量将在主要系列完成后至少六个月施用，并且剂量强度与主要系列中的剂量相同。</blockquote></p><p> “As we near the two-year mark in our fight against COVID-19, we have reached another critical milestone with the expanded authorization of a booster dose of our COVID-19 vaccine in individuals 18 years and older,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “With boosters, more adults will now have the opportunity to help preserve a high-level of protection against this disease. We are grateful to the FDA for their rigorous review, and the action taken today that we hope will help accelerate our path out of this pandemic.”</p><p><blockquote>董事长Albert Bourla表示：“随着我们抗击COVID-19的斗争接近两年，我们达到了另一个重要里程碑，扩大了对18岁及以上人群的COVID-19疫苗加强剂量的授权。”辉瑞公司主席兼首席执行官。“有了加强剂，更多的成年人现在将有机会帮助保持针对这种疾病的高水平保护。我们感谢FDA的严格审查，以及今天采取的行动，我们希望这将有助于加速我们走出这场大流行。”</blockquote></p><p> “Today’s FDA decision is supported by clinical data showing robust immune responses following a booster dose of our vaccine, exceeding what has been seen even after the completion of the highly-effective two-dose primary schedule,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “These data suggest a booster dose of our vaccine has the potential to maintain a high-level of protection against tested variants, including Delta.”</p><p><blockquote>BioNTech首席执行官兼联合创始人Ugur Sahin医学博士表示：“今天FDA的决定得到了临床数据的支持，这些数据显示，我们的疫苗加强剂量后产生了强大的免疫反应，甚至超过了高效的两剂主要计划完成后的免疫反应。”“这些数据表明，我们疫苗的加强剂量有可能对包括Delta在内的经过测试的变种保持高水平的保护。”</blockquote></p><p> In October, the companies announced positive topline results from the trial showing that a booster dose administered to individuals who previously received the Pfizer-BioNTech primary two-dose series demonstrated a relative vaccine efficacy of 95% when compared to those who did not receive a booster. Thus far, these are the first and only efficacy data disclosed from any randomized, controlled COVID-19 vaccine booster trial. The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no new safety concerns identified.</p><p><blockquote>10月，两家公司宣布了该试验的积极顶线结果，显示与未接受过辉瑞-BioNTech初级两剂系列的个人相比，对之前接受过辉瑞-BioNTech初级两剂系列的个人进行的加强剂量显示出95%的相对疫苗功效。到目前为止，这是第一个也是唯一一个从任何随机、对照的新冠肺炎疫苗加强试验中披露的疗效数据。不良事件概况与疫苗的其他临床安全性数据基本一致，未发现新的安全性问题。</blockquote></p><p> A booster dose of the Pfizer-BioNTech COVID-19 Vaccine was previously authorized by the FDA for emergency use after completion of a primary series in individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2, as well as eligible individuals who have completed primary vaccination with a different authorized COVID-19 vaccine.</p><p><blockquote>辉瑞-BioNTech新冠肺炎疫苗的加强剂量此前已被FDA授权在完成初级系列后紧急使用，用于65岁及以上的个人、18至64岁的严重新冠肺炎高风险个人、18至64岁经常在机构或职业中暴露于新型冠状病毒的个人，以及已完成不同授权新冠肺炎疫苗初级疫苗接种的合格个人。</blockquote></p><p> Pfizer and BioNTech continue to supply the vaccine, including sufficient volume for boosters, under their existing supply agreement with the U.S. government, which continues through April 2022. The companies do not expect that today’s news will impact the existing supply agreements in place with governments and international health organizations around the world.</p><p><blockquote>辉瑞和BioNTech根据与美国政府现有的供应协议继续供应疫苗，包括足够的疫苗剂量，该协议将持续至2022年4月。这些公司预计今天的消息不会影响与世界各地政府和国际卫生组织的现有供应协议。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144455380","content_text":"Pfizer and BioNTech SE stocks climbed about 2% in premarket trading after they received expanded U.S. FDA emergency use authorization of booster to include individuals 18 and older.\n\nPfizer Inc. and BioNTech SE today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 18 years of age and older. The booster dose is to be administered at least six months after completion of the primary series, and is the same dosage strength as the doses in the primary series.\n“As we near the two-year mark in our fight against COVID-19, we have reached another critical milestone with the expanded authorization of a booster dose of our COVID-19 vaccine in individuals 18 years and older,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “With boosters, more adults will now have the opportunity to help preserve a high-level of protection against this disease. We are grateful to the FDA for their rigorous review, and the action taken today that we hope will help accelerate our path out of this pandemic.”\n“Today’s FDA decision is supported by clinical data showing robust immune responses following a booster dose of our vaccine, exceeding what has been seen even after the completion of the highly-effective two-dose primary schedule,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “These data suggest a booster dose of our vaccine has the potential to maintain a high-level of protection against tested variants, including Delta.”\nIn October, the companies announced positive topline results from the trial showing that a booster dose administered to individuals who previously received the Pfizer-BioNTech primary two-dose series demonstrated a relative vaccine efficacy of 95% when compared to those who did not receive a booster. Thus far, these are the first and only efficacy data disclosed from any randomized, controlled COVID-19 vaccine booster trial. The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no new safety concerns identified.\nA booster dose of the Pfizer-BioNTech COVID-19 Vaccine was previously authorized by the FDA for emergency use after completion of a primary series in individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2, as well as eligible individuals who have completed primary vaccination with a different authorized COVID-19 vaccine.\nPfizer and BioNTech continue to supply the vaccine, including sufficient volume for boosters, under their existing supply agreement with the U.S. government, which continues through April 2022. The companies do not expect that today’s news will impact the existing supply agreements in place with governments and international health organizations around the world.","news_type":1,"symbols_score_info":{"PFE":0.9,"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":2023,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871708992,"gmtCreate":1637109801542,"gmtModify":1637109856444,"author":{"id":"4097912578278380","authorId":"4097912578278380","name":"Rosechin","avatar":"https://static.tigerbbs.com/b609bc0ae15909da0a6fbf0d048f7ebd","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097912578278380","authorIdStr":"4097912578278380"},"themes":[],"htmlText":"Good to invest this sharr","listText":"Good to invest this sharr","text":"Good to invest this sharr","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871708992","repostId":"2183024810","repostType":2,"repost":{"id":"2183024810","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1636978318,"share":"https://www.laohu8.com/m/news/2183024810?lang=zh_CN&edition=full","pubTime":"2021-11-15 20:11","market":"hk","language":"en","title":"Online Gaming Business Drives Sohu's 37% Revenue Growth In Q3<blockquote>网络游戏业务推动搜狐第三季度营收增长37%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2183024810","media":"Benzinga","summary":"\n","content":"<p><html><body><ul> <li><strong>Sohu.com Ltd</strong> (NASDAQ:SOHU) reported third-quarter FY21 revenue growth of 37% year-on-year to $216 million. Revenue improved 6% quarter-over-quarter.</li> <li>Brand advertising revenues declined 18% Y/Y to $34 million due to decreases in portal advertising revenues. </li> <li>Online game revenues grew 65% Y/Y to $167 million, mainly contributed by TLBB Vintage.</li> <li>The gross margin was 74%, expanding 800 basis points Y/Y and contracting 200 basis points sequentially. The gross margin for online games was 83% versus 80% last year and 89% in 2Q21.</li> <li>Non-GAAP earnings per ADS were $0.44.</li> <li>Sohu held $1.57 billion in cash and equivalents.</li> <li>Average monthly active user accounts for Changyou<strong> </strong>PC games increased 3% Y/Y to 2 million, mainly due to the TLBB Vintage. Average MAU for Changyou<strong> </strong>mobile games rose 22% Y/Y to 4.6 million, mainly due to the launch of Little Raccoon: Heroes.</li> <li>\"Overall, we delivered better than expected top line and bottom line performance thanks to the solid performance of our online game business,\" Chair and CEO Dr. Charles Zhang said.</li> <li><strong>Share buyback:</strong> The board authorized a share repurchase program of up to $100 million of the outstanding ADSs of Sohu over the next twelve months.</li> <li><strong>Outlook</strong>: Sohu sees Q4 brand advertising revenue decrease 26%-33% Y/Y to $28 million - $31 million.</li> <li>It sees Q4 online game revenues growth 23%-29% to $140 million - $150 million.</li> <li><strong>Price Action:</strong> SOHU shares closed higher by 0.09% at $21.57 on Friday.</li> </ul> </body></html></p><p><blockquote><html><body><ul><li><strong>搜狐网有限公司</strong>（纳斯达克：搜狐）公布2021财年第三季度收入同比增长37%至2.16亿美元。收入环比增长6%。</li><li>由于门户网站广告收入下降，品牌广告收入同比下降18%至3400万美元。</li><li>在线游戏收入同比增长65%至1.67亿美元，主要由TLBB Vintage贡献。</li><li>毛利率为74%，同比增长800个基点，环比收缩200个基点。网络游戏的毛利率为83%，而去年为80%，2021年第二季度为89%。</li><li>非GAAP每股ADS收益为0.44美元。</li><li>搜狐持有15.7亿美元现金及等价物。</li><li>畅游的平均月活跃用户账户<strong></strong>PC游戏同比增长3%至200万款，主要得益于TLBB复古游戏。畅游的平均MAU<strong></strong>手机游戏同比增长22%至460万，主要得益于《小浣熊：英雄》的推出。</li><li>董事长兼首席执行官Charles Zhang博士表示：“总体而言，由于在线游戏业务的稳健表现，我们的营收和利润表现好于预期。”</li><li><strong>股份回购：</strong>董事会批准了一项股票回购计划，在未来12个月内回购搜狐已发行美国存托股最多1亿美元。</li><li><strong>世界观</strong>：搜狐预计第四季度品牌广告收入同比下降26%-33%至2800万美元至3100万美元。</li><li>预计第四季度在线游戏收入将增长23%-29%，达到1.4亿-1.5亿美元。</li><li><strong>价格走势：</strong>搜狐股价周五收盘上涨0.09%，至21.57美元。</li></ul></body></html></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Online Gaming Business Drives Sohu's 37% Revenue Growth In Q3<blockquote>网络游戏业务推动搜狐第三季度营收增长37%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOnline Gaming Business Drives Sohu's 37% Revenue Growth In Q3<blockquote>网络游戏业务推动搜狐第三季度营收增长37%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-11-15 20:11</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><html><body><ul> <li><strong>Sohu.com Ltd</strong> (NASDAQ:SOHU) reported third-quarter FY21 revenue growth of 37% year-on-year to $216 million. Revenue improved 6% quarter-over-quarter.</li> <li>Brand advertising revenues declined 18% Y/Y to $34 million due to decreases in portal advertising revenues. </li> <li>Online game revenues grew 65% Y/Y to $167 million, mainly contributed by TLBB Vintage.</li> <li>The gross margin was 74%, expanding 800 basis points Y/Y and contracting 200 basis points sequentially. The gross margin for online games was 83% versus 80% last year and 89% in 2Q21.</li> <li>Non-GAAP earnings per ADS were $0.44.</li> <li>Sohu held $1.57 billion in cash and equivalents.</li> <li>Average monthly active user accounts for Changyou<strong> </strong>PC games increased 3% Y/Y to 2 million, mainly due to the TLBB Vintage. Average MAU for Changyou<strong> </strong>mobile games rose 22% Y/Y to 4.6 million, mainly due to the launch of Little Raccoon: Heroes.</li> <li>\"Overall, we delivered better than expected top line and bottom line performance thanks to the solid performance of our online game business,\" Chair and CEO Dr. Charles Zhang said.</li> <li><strong>Share buyback:</strong> The board authorized a share repurchase program of up to $100 million of the outstanding ADSs of Sohu over the next twelve months.</li> <li><strong>Outlook</strong>: Sohu sees Q4 brand advertising revenue decrease 26%-33% Y/Y to $28 million - $31 million.</li> <li>It sees Q4 online game revenues growth 23%-29% to $140 million - $150 million.</li> <li><strong>Price Action:</strong> SOHU shares closed higher by 0.09% at $21.57 on Friday.</li> </ul> </body></html></p><p><blockquote><html><body><ul><li><strong>搜狐网有限公司</strong>（纳斯达克：搜狐）公布2021财年第三季度收入同比增长37%至2.16亿美元。收入环比增长6%。</li><li>由于门户网站广告收入下降，品牌广告收入同比下降18%至3400万美元。</li><li>在线游戏收入同比增长65%至1.67亿美元，主要由TLBB Vintage贡献。</li><li>毛利率为74%，同比增长800个基点，环比收缩200个基点。网络游戏的毛利率为83%，而去年为80%，2021年第二季度为89%。</li><li>非GAAP每股ADS收益为0.44美元。</li><li>搜狐持有15.7亿美元现金及等价物。</li><li>畅游的平均月活跃用户账户<strong></strong>PC游戏同比增长3%至200万款，主要得益于TLBB复古游戏。畅游的平均MAU<strong></strong>手机游戏同比增长22%至460万，主要得益于《小浣熊：英雄》的推出。</li><li>董事长兼首席执行官Charles Zhang博士表示：“总体而言，由于在线游戏业务的稳健表现，我们的营收和利润表现好于预期。”</li><li><strong>股份回购：</strong>董事会批准了一项股票回购计划，在未来12个月内回购搜狐已发行美国存托股最多1亿美元。</li><li><strong>世界观</strong>：搜狐预计第四季度品牌广告收入同比下降26%-33%至2800万美元至3100万美元。</li><li>预计第四季度在线游戏收入将增长23%-29%，达到1.4亿-1.5亿美元。</li><li><strong>价格走势：</strong>搜狐股价周五收盘上涨0.09%，至21.57美元。</li></ul></body></html></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SOHU":"搜狐"},"source_url":"https://www.benzinga.com/news/earnings/21/11/24084879/online-gaming-business-drives-sohus-37-revenue-growth-in-q3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2183024810","content_text":"Sohu.com Ltd (NASDAQ:SOHU) reported third-quarter FY21 revenue growth of 37% year-on-year to $216 million. Revenue improved 6% quarter-over-quarter.\nBrand advertising revenues declined 18% Y/Y to $34 million due to decreases in portal advertising revenues. \nOnline game revenues grew 65% Y/Y to $167 million, mainly contributed by TLBB Vintage.\nThe gross margin was 74%, expanding 800 basis points Y/Y and contracting 200 basis points sequentially. The gross margin for online games was 83% versus 80% last year and 89% in 2Q21.\nNon-GAAP earnings per ADS were $0.44.\nSohu held $1.57 billion in cash and equivalents.\nAverage monthly active user accounts for Changyou PC games increased 3% Y/Y to 2 million, mainly due to the TLBB Vintage. Average MAU for Changyou mobile games rose 22% Y/Y to 4.6 million, mainly due to the launch of Little Raccoon: Heroes.\n\"Overall, we delivered better than expected top line and bottom line performance thanks to the solid performance of our online game business,\" Chair and CEO Dr. Charles Zhang said.\nShare buyback: The board authorized a share repurchase program of up to $100 million of the outstanding ADSs of Sohu over the next twelve months.\nOutlook: Sohu sees Q4 brand advertising revenue decrease 26%-33% Y/Y to $28 million - $31 million.\nIt sees Q4 online game revenues growth 23%-29% to $140 million - $150 million.\nPrice Action: SOHU shares closed higher by 0.09% at $21.57 on Friday.","news_type":1,"symbols_score_info":{"SOHU":0.9}},"isVote":1,"tweetType":1,"viewCount":3058,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}